Linc00963: A novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2041-2049

  Wang, Lijuan ^a   Han, Suxia ^a   Jin, Guihua ^a   Zhou, Xia ^a   Li, Meng ^a   Ying, Xia ^a   Wang, Le ^a   Wu, Huili ^a   Zhu, Qing ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

AKT; Castration resistant prostate cancer; Epidermal growth factor receptor; Linc00963; Long non coding RNA

Indexed keywords

ADAMTS1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GROWTH DIFFERENTIATION FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HYALURONOGLUCOSAMINIDASE; INTERCELLULAR ADHESION MOLECULE 1; LINC00963; LONG UNTRANSLATED RNA; MYOSIN LIGHT CHAIN KINASE; NEUROPILIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S100 CALCIUM BINDING PROTEIN G; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; ANDROGEN; ANDROGEN RECEPTOR; LINC00963 PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN; EGFR PROTEIN, HUMAN;

ANDROGEN DEPENDENCE; ANDROGEN INDEPENDENCE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; CANCER CELL CULTURE; CELL COUNT; CELL TRANSFORMATION; FLOW CYTOMETRY; GENE EXPRESSION; LNCAP CELL LINE; MICROARRAY ANALYSIS; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TRANSACTIVATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CASTRATION RESISTANT PROSTATE CANCER; CELL LINE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR;

APOPTOSIS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, LONG NONCODING;

EID: 84899505705     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2363     Document Type: Article

References (36)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Lee AK: Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 16: 20-28, 2006.
3. Molina A and Belldegrun A: Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 185: 787-794, 2011.
4. Mlcochova J, Faltejskova P, Nemecek R, Svoboda M and Slaby O: MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol 139: 1615-1624, 2013.
5. Shuch B, Mikhail M, Satagopan J, et al: Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 22: 4725-4729, 2004.
6. Syed S: Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls. Cancer 98: 2088-2090, 2003.
7. Traish AM and Morgentaler A: Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer 101: 1949-1956, 2009.
8. Antonarakis ES, Carducci MA and Eisenberger MA: Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 291: 1-13, 2010.
9. Guttman M, Amit I, Garber M, et al: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458: 223-227, 2009.
10. Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov 1: 391-407, 2011.
11. Gupta RA, Shah N, Wang KC, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464: 1071-1076, 2010.
12. Reis EM, Nakaya HI, Louro R, et al: Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene 23: 6684-6692, 2004.
13. Prensner JR, Iyer MK, Balbin OA, et al: Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29: 742-749, 2011.
14. Ji P, Diederichs S, Wang W, et al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22: 8031-8041, 2003.
15. Petrovics G, Zhang W, Makarem M, et al: Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 23: 605-611, 2004.
16. Srikantan V, Zou Z, Petrovics G, et al: PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci USA 97: 12216-12221, 2000.
17. Chung S, Nakagawa H, Uemura M, et al: Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 102: 245-252, 2011.
18. Cui Z, Ren S, Lu J, et al: The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol 31: 1117-1123, 2013.
19. Lin R, Maeda S, Liu C, Karin M and Edgington TS: A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 26: 851-858, 2007.
20. de Kok JB, Verhaegh GW, Roelofs RW, et al: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62: 2695-2698, 2002.
21. Hessels D, Klein Gunnewiek JM, van Oort I, et al : DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-16, 2003.
22. Xie BX, Zhang H, Yu L, et al : The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J Androl 12: 405-414, 2010.
23. Horoszewicz JS, Leong SS, Kawinski E, et al: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
24. Thalmann GN, Anezinis PE, Chang SM, et al : Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581, 1994.
25. Chen L, Mooso BA, Jathal MK, et al: Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res 17: 6218-6228, 2011.
26. Gutschner T and Diederichs S: The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9: 703-719, 2012.
27. Wang KC and Chang HY: Molecular mechanisms of long non-coding RNAs. Mol Cell 43: 904-914, 2011.
28. Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell 136: 629-641, 2009.
29. Roberts LD, Murray AJ, Menassa D, Ashmore T, Nicholls AW and Griffin JL: The contrasting roles of PPARdelta and PPARgamma in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue. Genome Biol 12: R75, 2011.
30. Cheng W, Zhang Z and Wang J: Long noncoding RNAs: New players in prostate cancer. Cancer Lett 339: 8-14, 2013.
31. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59: 5975-5979, 1999.
32. Bu D, Yu K, Sun S, et al: NONCODE v3.0: integrative annotation of long noncoding RNAs. Nucleic Acids Res 40: D210-D215, 2012.
33. Takayama K, Horie-Inoue K, Katayama S, et al: Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J 32: 1665-1680, 2013.
34. Mimeault M and Batra SK: Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27: 1-22, 2006.
35. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61: 6276-6280, 2001.
36. Xie BX, Zhang H, Wang J, et al: Analysis of differentially expressed genes in LNCaP prostate cancer progression model. J Androl 32: 170-182, 2011.